UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 821, 2014

SAVIENT PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

0-15313

13-3033811

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

400 Crossing Boulevard

Bridgewater, NJ

08807

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (732) 418-9300

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 17.0201. ~~Termination~~Regulation ofFD ~~a Material Definitive Agreement~~Disclosure.

~~The~~As ~~information~~previously ~~contained~~announced, ~~in Item~~on October 214, 2013, Savient Pharmaceuticals, Inc.01 is(the ~~incorporated~~“Company”) byand ~~reference~~its ~~into~~subsidiary, ~~this~~Savient ~~Item~~Pharma Holdings, Inc. (collectively, the “Debtors”), filed voluntary petitions (the “Chapter 11 Cases”) for relief under Chapter 111 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).~~02.~~

~~Item~~On January 21, ~~2.01.~~2014, ~~Completion~~the ofDebtors ~~Acquisition~~filed ortheir ~~Disposition~~monthly operating report for the period of ~~Assets~~December 1, 2013 through December 31, 2013 (the “Monthly Operating Report”) with the Bankruptcy Court. The Monthly Operating Report is attached hereto as Exhibit 99.1.

AsCautionary ~~previously~~Statement ~~disclosed,~~Regarding ~~on October 14, 2013, Savient Pharmaceuticals, Inc. (~~the ~~“Company”)~~Monthly ~~and~~Operating ~~its~~Report subsidiary, Savient Pharma Holdings, Inc. (collectively, the “Debtors”), filed voluntary petitions (the “Chapter 11 Cases”) for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).

OnThe ~~December 11,~~Company ~~2013,~~cautions investors and potential investors not to place undue reliance upon the ~~Company~~information ~~announced~~contained ~~that~~in the Monthly Operating Report, ~~pursuant~~which towas not prepared for the purpose of providing the basis for an ~~auction~~investment ~~conducted~~decision onrelating ~~December 10,~~to ~~2013~~any ~~under~~of the ~~provisions~~securities of the Company. The Monthly Operating Report is limited in scope and has been prepared solely for the purpose of ~~Section 363~~complying with requirements of the Bankruptcy ~~Code~~Court. ~~(the~~The ~~“Auction”)~~Monthly Operating Report was not reviewed by independent accountants, itis ~~had~~in ~~entered~~a ~~into~~format anprescribed ~~acquisition~~by ~~agreement~~applicable (bankruptcy laws, and is subject to future adjustment. The financial statements in the ~~“Acquisition~~Monthly ~~Agreement”)~~Operating Report are not prepared in accordance with ~~Crealta~~accounting ~~Pharmaceuticals~~principles ~~LLC~~generally accepted in the United States (“~~Crealta~~GAAP”) ~~through~~and, ~~which~~therefore, ~~Crealta~~may ~~would~~exclude ~~acquire substantially~~items ~~all~~required ofby ~~the~~GAAP, ~~Debtors’~~such ~~assets~~as ~~and~~ certain ~~liabilities~~reclassifications, eliminations, accruals, valuations and disclosures. The Monthly Operating Report also contains information for ~~gross~~periods ~~proceeds~~which are shorter or otherwise different from the historical periods required in the Company’s reports pursuant to the Securities Exchange Act of ~~approximately~~1934, ~~$120.4~~as ~~million~~amended (the “~~Sale~~Exchange ~~Transaction~~Act”)., Asand ~~previously~~such ~~disclosed,~~information onmight ~~December 13,~~not ~~2013,~~be indicative of the ~~Bankruptcy~~Company’s ~~Court~~financial ~~approved~~condition anor ~~order authorizing~~operating results for a period that would be reflected in the ~~Sale~~Company’s ~~Transaction~~financial statements ~~with~~or ~~Crealta~~in its reports pursuant to the ~~Acquisition~~Exchange ~~Agreement~~Act. Information set forth in the Monthly Operating Report should not be viewed as indicative of future results.

OnCautionary ~~January 9,~~Statement ~~2014,~~Regarding ~~the~~Forward-Looking ~~Company~~Statements completed the Sale Transaction. With the closing of the Sale Transaction, the Debtors have completed the disposition of substantially all of their assets, including all KRYSTEXXA® assets. The Company has agreed to provide to Crealta certain support services in connection with the transition of the business through January 31, 2014.

~~As previously~~This ~~disclosed~~Current Report on Form 8-K and Exhibit 99.1 hereto (collectively, this “Current Report”) may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on ~~October 14~~current expectations, ~~2013~~estimates, ~~the~~forecasts, ~~Debtors~~and projections ~~entered~~as ~~into~~well anas ~~acquisition~~the ~~agreement~~current (beliefs and assumptions of the Company’s management. Forward-looking statements may be identified by words such as “~~Stalking~~anticipate,” ~~Horse~~“estimate,” ~~Agreement~~“expect,”) ~~with~~“project,” “intend,” US“plan,” ~~WorldMeds~~“believe,” ~~LLC~~“may,” (“USpredict,” ~~WorldMeds~~“will,”) “would,” “could,” “should,” “target” and ~~its~~similar ~~subsidiary~~expressions. ~~Sloan~~All ~~Holdings~~statements Ccontained in this Current Report that are not statements of historical fact and other estimates, projections, future trends and the outcome of events that have not yet occurred referenced in this Current Report should be considered forward-looking statements.V. Actual ~~(“Sloan”)~~results or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties, ~~pursuant~~including, among others, the potential adverse impact of the Chapter 11 Cases on the Company’s liquidity, changes in the Company’s ability to ~~which~~meet ~~Sloan~~financial ~~agreed~~obligations during the Chapter 11 process or to ~~acquire~~maintain contracts that are critical to the Company’s wind-down of its affairs, the outcome or timing of the Chapter 11 process, the effect of the Chapter 11 Cases or the sale of substantially all of the ~~Debtors~~Company’s assets ~~and~~to ~~certain~~Crealta ~~liabilities~~Pharmaceuticals ~~for~~LLC an(the ~~aggregate~~“Sale ~~purchase~~Transaction”) ~~price~~on the Company’s relationships with third parties, regulatory authorities, employees and consultants in connection with the Company’s wind-down of ~~approximately~~its ~~$55~~affairs, ~~million~~proceedings that may be brought by third parties in connection with the Chapter 11 process, ~~subject~~the ability of the Company to ~~receipt~~fund the wind-down of ~~higher~~its oraffairs ~~otherwise~~and ~~better~~the ~~bids~~timing or atamount of any distributions to the ~~Auction~~Company’s stakeholders. InFor ~~connection~~a ~~with~~discussion ~~the~~of ~~closing~~some of the ~~Sale~~additional ~~Transaction~~risks and important factors that the Company believes could cause actual results or events to differ from the forward-looking statements that it makes, see the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Quarterly Report on ~~January~~Form 10-Q for the quarter ended September 930, ~~2014~~2013. In addition, new risks and uncertainties emerge from time to time, and it is not possible for the Company ~~terminated~~to predict or assess the ~~Stalking~~impact ~~Horse~~of ~~Agreement~~every ~~pursuant~~factor tothat may cause its ~~terms~~actual ~~and~~results ~~paid~~or $2events to differ from those contained in any forward-looking statements.4 ~~million~~Accordingly, you should not place undue reliance on any forward-looking statements contained in this Current Report. Any forward-looking statements speak only as of the date of this Current Report. The Company undertakes no obligation to USpublicly ~~WorldMeds~~update forward-looking statements, whether as a ~~break-up~~result ~~fee~~of ~~and~~new ~~expense reimbursement~~information, future events or otherwise.

~~Item~~Limitation ~~5.02.~~on ~~Departure~~Incorporation ofby ~~Directors~~Reference ~~or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~

~~(b)~~ In ~~connection~~accordance with ~~the~~General ~~closing~~Instruction ofB.2 ~~the Sale Transaction and in anticipation~~ of ~~the winding down of the Debtors’ affairs, on January~~Form 8-K, ~~2014, directors Ginger Constantine, MD, David P. Meeker, MD, David Y. Norton, Robert G. Savage and Virgil Thompson resigned from~~ the ~~board~~information ofin ~~directors~~this ofCurrent ~~the~~Report ~~Company,~~is ~~effective~~being asfurnished offor ~~the closing of~~informational ~~the~~purposes ~~Sale~~only ~~Transaction.~~and ~~The~~shall ~~sole~~not ~~remaining~~be ~~director~~deemed of“filed” ~~the~~for ~~Company~~purposes ~~following such resignations is Stephen O. Jaeger. Also in connection with the closing~~ of ~~the~~Section 18 ~~Sale Transaction and in anticipation~~ of the ~~winding~~Exchange ~~down~~Act, ofor ~~the~~otherwise ~~Debtors’~~subject ~~affairs,~~to ~~on January 8, 2014,~~ the ~~following~~liabilities ~~individuals were removed as officers~~ of ~~the~~that ~~Company~~section, ~~effective~~nor ~~January 15,~~shall ~~2014:~~such ~~Philip~~information K.be ~~Yachmetz,~~deemed ~~Co-President~~incorporated ~~and~~by ~~Chief~~reference ~~Business~~in ~~Officer,~~any ~~John~~filing ~~P. Hamill, Co-President and Chief Financial Officer, Richard~~under ~~Crowley,~~the ~~Co-President~~Securities ~~and~~Act ~~Chief Operating Officer, Kenneth M. Bahrt, MD, Senior Vice President and Chief Medical Officer and David Gionco, Group VP~~ of ~~Finance and Chief Accounting Officer.~~

~~(c)~~ 1933, Onas ~~January 8~~amended, ~~2014,~~except ~~Mathew~~as ~~Bazley~~otherwise ~~was~~expressly ~~appointed~~stated ~~Chief~~in ~~Liquidation~~such ~~Officer,~~filing. ~~President~~The ~~and~~filing ~~Secretary~~ of ~~the~~this ~~Company,~~current ~~effective January~~report (including Exhibit ~~15,~~99.1 ~~2014~~attached hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.

~~Mr. Bazley,~~Additional ~~41,~~Information ~~has~~regarding ~~served as~~ the ~~Company’s~~Chapter ~~Assistant~~11 ~~General Counsel since February 2013. Prior to that~~Cases ~~time, Mr. Bazley was an attorney at Skadden, Arps, Slate, Meagher and Flom LLP, from 2006 to 2013. From 2003 to 2006, Mr. Bazley was an attorney at the U.S. Securities and Exchange Commission.~~

~~Item~~Additional 5information regarding the Chapter 11 Cases is available at www.03gcginc.com/cases/svnt. This ~~Amendments~~link is provided for convenience only. Such information shall not be deemed to ~~Articles~~be incorporated by reference herein. As a result of ~~Incorporation~~the orconsummation ~~Bylaws;~~of ~~Change~~the inSale ~~Fiscal~~Transaction, ~~Year~~investors should no longer refer to the Company’s former company website for information.

~~On January 8,~~Item ~~2014,~~9.01. ~~the~~Financial ~~board~~Statements ~~of directors of the Company adopted an amendment to the Company’s By-Laws to reduce the minimum number of directors constituting the whole board of directors from three to one~~ and ~~to eliminate the requirement that the Company have a vice president or treasurer~~Exhibits. ~~The amendment to the Company’s By-Laws is attached hereto as Exhibit 3.1.~~

~~Cautionary~~(d) Exhibits: ~~Statement Regarding Forward-Looking Statements~~

~~This Current Report on Form 8-K (this “Current Report”) may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995~~99.1 ~~Forward-looking~~Monthly ~~statements~~Operating are those involving future events and future results that are based on current expectations, estimates, forecasts, and projections as well as the current beliefs and assumptions of the Company’s management. Forward-looking statements may be identified by words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “may,” “predict,” “will,” “would,” “could,” “should,” “target” and similar expressions. All statements contained in this Current Report ~~that~~for ~~are not statements of historical fact and other estimates, projections, future trends and~~ the ~~outcome~~Period of ~~events~~December that have not yet occurred referenced in this Current Report should be considered forward-looking statements. Actual results or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties1, ~~including,~~2013 ~~among~~through ~~others,~~December ~~the potential adverse impact of the Chapter 11 Cases on the Company’s liquidity~~31, changes in the Company’s ability to meet financial obligations during the Chapter 11 process or to maintain contracts that are critical to the Company’s wind-down of its affairs, the outcome or timing of the Chapter 11 process, the effect of the Chapter 11 Cases or the Sale Transaction on the Company’s relationships with third parties, regulatory authorities, employees and consultants in connection with the Company’s wind-down of its affairs, proceedings that may be brought by third parties in connection with the Chapter 11 process, the ability of the Company to fund the wind-down of its affairs and the timing or amount of any distributions to the Company’s stakeholders. For a discussion of some of the additional risks and important factors that the Company believes could cause actual results or events to differ from the forward-looking statements that it makes, see the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013~~. In addition~~, ~~new~~dated ~~risks~~January ~~and uncertainties emerge from time to time~~21, ~~and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results or events to differ from those contained in any forward-looking statements~~2014. Accordingly, you should not place undue reliance on any forward-looking statements contained in this Current Report. Any forward-looking statements speak only as of the date of this Current Report. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

~~Additional~~2 ~~Information Regarding the Chapter 11 Cases~~

~~Additional~~SIGNATURES information regarding the Chapter 11 Cases is available at www.gcginc.com/cases/svnt. This link is provided for convenience only. Such information shall not be deemed to be incorporated by reference herein. As a result of the consummation of the Sale Transaction, investors should no longer refer to the Company’s former company website for information.

~~Item~~Pursuant ~~9.01.~~to ~~Financial~~the ~~Statements~~requirements ~~and~~of ~~Exhibits~~the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(b) Pro Forma Financial Information


	SAVIENT PHARMACEUTICALS, INC.

Date: January 22, 2014	By:	/s/ Mathew C. Bazley
		Name:	Mathew C. Bazley
		Title:	Chief Liquidation Officer, President and Secretary

~~The~~INDEX ~~Company~~TO isEXHIBITS currently unable to prepare pro forma financial information reflecting the transactions described in Item 2.01 of this Current Report without unreasonable effort or expense and thus such information is not reasonably available to the Company within the meaning of Rule 12b-21 under the Securities Exchange Act of 1934, as amended. As a debtor-in-possession under the Bankruptcy Code, the Company files monthly operating reports with the Bankruptcy Court, which reports include financial statements that are limited in scope and prepared solely for the purpose of complying with requirements of the Bankruptcy Court. The Company cautions investors and potential investors not to place undue reliance upon the information contained in the monthly operating reports, which are not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company.

(d) Exhibits


Exhibit No.		Description

99.1		Monthly Operating Report for the Period of December 1, 2013 through December 31, 2013, dated January 21, 2014.

3.1 Amendment to the By-Laws of Savient Pharmaceuticals, Inc., effective January 8, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INDEX TO EXHIBITS

ExhibitNo.		Description
3.1		Amendment to the By-Laws of Savient Pharmaceuticals, Inc., effective January 8, 2014.

SAVIENT PHARMACEUTICALS, INC.

Date: January 10, 2014

/s/ Philip K. Yachmetz

Philip K. Yachmetz

Co-President and Chief Business Officer

Filing Compare · SAVIENT PHARMACEUTICALS INC